



Regeneron Genetics Center

Regeneron Genetics Center (RGC) is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics. The primary goal of RGC is to improve patient outcomes by identifying novel drug targets, clinical indications for development programs, and genomic biomarkers for pharmacogenomic applications.

Therapeutic Areas of Interest



Oncology



Cardiovascular



Metabolic



Musculoskeletal



Ophthalmology



Infectious Diseases



Respiratory Diseases



Immune Diseases



Founder & Special Populations



Neurology

“RGC applies the best and latest technologies in sequencing and analytics to harness the power of human genetics to create game changing new medicines.”

– Aris Baras, Head of RGC

RGC Milestones

- 2013** Regeneron sought to further explore the human genetic code and RGC was born. Launched foundational initiative with Geisinger to sequence 100k participants.
- 2017** Discovered inhibition of ANGPTL3 gene in humans and mice is associated with decreased levels of all 3 major lipid fractions and protection from atherosclerotic cardiovascular disease.
- 2018** Uncovered loss-of-function variant in HSD17B13 gene associated with reduced risk of chronic liver disease. Partnered with UK Biobank to accelerate our research goals.
- 2020** Sequenced our 1,000,000th exome – first organization in the world to do so.
- 2021** Discovered rare genetic mutations in GPR75 gene associated with protection against obesity.
- 2022** Uncovered a novel association between rare mutations in the CIDEB gene and protection from liver damage and disease.
- 2023** 10-year anniversary of RGC's founding.

Science - Led

World-class scientists & researchers.

250+
publications authored
based on RGC data

1st
genome center in the cloud
with fully automated analysis pipelines

RGC Collaborations

Global network of collaborator institutions.

130+
collaborations

23
countries

The Database

Largest & most diverse in the world.

2.5M
exomes sequenced
and counting

650K
underrepresented
individuals sequenced

Development of Therapeutics

Our mission: genetics to therapeutics, designed for all.

6
genetics medicines
programs in the clinic

30+
therapeutic programs started
from novel RGC targets or known
genes with novel RGC insights

20+
novel genetic
targets discovered

50+
novel protective
genetics discoveries

Science Obsessed, Human Inspired.